News from the FDA/CDC
FDA/CDC
Cotempla XR-ODT approved for children, adolescents with ADHD
Methylphenidate for ADHD now comes in a more convenient disintigrating tablet.
FDA/CDC
Mydayis approved for teens, adults with ADHD
Treatment can lead to improved symptoms of ADHD that can last up to 16 hours, phase III studies show.
FDA/CDC
Extended-release Aristada OK’d for 2-month dosing for schizophrenia
The new bimonthly long-acting injectable is another option aimed at improving adherence among patients.
News from the FDA/CDC
FDA asks drug maker to shelve Opana ER
This marks the first time the agency has acted to remove an opioid pain medication because of the public health consequences of abuse.
FDA/CDC
FDA approves generic Strattera for pediatric, adult ADHD patients
Generic atomoxetine will help more people in need find treatment.
FDA/CDC
Alzheimer’s mortality in U.S. grew from 1999 to 2014
Mortality rose dramatically in some states and ethnicities.
FDA/CDC
FDA approves new treatment for episodic cluster headaches in adults
The Food and Drug Administration announced April 18 the approval of the gammaCore device to treat pain associated with episodic cluster headache...
News from the FDA/CDC
FDA approves Ingrezza for tardive dyskinesia in adults
The Food and Drug Administration has approved valbenazine capsules as the first drug for tardive dyskinesia.
FDA/CDC
FDA approves deutetrabenazine for Huntington’s-associated chorea
Deutetrabenazine is only the second product approved to treat Huntington’s in any capacity, and it is the first in nearly a decade.
FDA/CDC
FDA approves safinamide to treat Parkinson’s disease
The drug is indicated for use as an add-on to levodopa or carbidopa to help in reducing “off” time.
News from the FDA/CDC
Brodalumab approved for psoriasis with REMS required
The FDA has approved brodalumab for treating moderate to severe psoriasis, with a REMS that addresses a risk of suicidal ideation and behavior...